Literature DB >> 9347311

Angiotensin II receptors in endothelial cells.

M E Pueyo1, J B Michel.   

Abstract

1. Angiotensin II (Ang II), the main effector of the renin-angiotensin system, exerts its vasoconstrictory and trophic actions on smooth muscle cells via AT1 receptors. However, Ang II does not act only on smooth muscle cells, as Ang II receptors are also present in endothelial cells. 2. The receptor type on these cells differs depending on the origin of the endothelium and the species. The rat endothelial receptors are mostly of the AT1 type, but AT2 receptors have also been found. The pharmacological characteristics of the AT1 receptors on endothelial cells are similar to those of other cell types. 3. Ang II stimulates phospholipase C and phospholipase A2 activation via the AT1 receptor in endothelial cells. Ang II also stimulates the tyrosine phosphorylation of several proteins in these cells. 4. Some studies suggest that the AT1 receptor mediates the release of vasodilator molecules by endothelial cells and could modulate Ang II effect on smooth muscle cells. Ang II may also inhibit endothelial cell growth via the AT2 receptor. Finally, endothelial Ang II receptors may be implicated in the regulation of fibrinolysis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9347311     DOI: 10.1016/s0306-3623(97)00021-9

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  16 in total

1.  Differential role of angiotensin II receptor subtypes on endothelial superoxide formation.

Authors:  H Y Sohn; U Raff; A Hoffmann; T Gloe; K Heermeier; J Galle; U Pohl
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

2.  Vascular responses of the extremities to transdermal application of vasoactive agents in Caucasian and African descent individuals.

Authors:  Matthew J Maley; James R House; Michael J Tipton; Clare M Eglin
Journal:  Eur J Appl Physiol       Date:  2015-04-04       Impact factor: 3.078

3.  Protective role of the matricellular protein CCN3 in abdominal aortic aneurysm.

Authors:  Pavel Uhrin; Johannes M Breuss
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

4.  Angiotensinergic stimulation of vascular endothelium in mice causes hypotension, bradycardia, and attenuated angiotensin response.

Authors:  Ramaswamy Ramchandran; Takanobu Takezako; Yasser Saad; Linda Stull; Bruno Fink; Hirotsugu Yamada; Sergey Dikalov; David G Harrison; Christine Moravec; Sadashiva S Karnik
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-05       Impact factor: 11.205

5.  Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation.

Authors:  Jeong-A Kim; Hyun-Ju Jang; Luis A Martinez-Lemus; James R Sowers
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-10-25       Impact factor: 4.310

6.  Lack of involvement of endothelin-1 in angiotensin II-induced contraction of the isolated rat tail artery.

Authors:  Y Jiang; C R Triggle
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

7.  Angiotensin-(1-7) is involved in the endothelium-dependent modulation of phenylephrine-induced contraction in the aorta of mRen-2 transgenic rats.

Authors:  Virgínia S Lemos; Steyner F Côrtes; Denise M R Silva; Maria J Campagnole-Santos; Robson A S Santos
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

Review 8.  Polarized Proteins in Endothelium and Their Contribution to Function.

Authors:  Abigail G Wolpe; Claire A Ruddiman; Phillip J Hall; Brant E Isakson
Journal:  J Vasc Res       Date:  2021-01-27       Impact factor: 1.934

9.  Endothelial transcriptomics reveals activation of fibrosis-related pathways in hypertension.

Authors:  Jonathan W Nelson; Mohammed Z Ferdaus; James A McCormick; Jessica Minnier; Sanjiv Kaul; David H Ellison; Anthony P Barnes
Journal:  Physiol Genomics       Date:  2018-01-08       Impact factor: 3.107

Review 10.  Functional ACE2 deficiency leading to angiotensin imbalance in the pathophysiology of COVID-19.

Authors:  Joshua R Cook; John Ausiello
Journal:  Rev Endocr Metab Disord       Date:  2021-07-01       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.